Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Epistem Holdings plc. (2/19/16). "Press Release: Update on CEO Appointment".

Organisations Organisation Epistem Holdings plc
  Group Epistem (Group)
  Organisation 2 Leica Biosystems (biosystems division of Leica Microsystems)
  Group Danaher (Group)
Products Product personalised medicine / precision medicine
  Product 2 Genedrive™ molecular device
Persons Person Budd, David (Epistem 201603– CEO before Leica Biosystems + Siemens Healthcare Diagnostics + Bayer Diagnostics)
  Person 2 Gilham, Ian D. (Axis-Shield 200801 CEO– before COO)

Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, is pleased to announce that, following his appointment as Chief Executive Officer and as Board Director as announced on 13 January 2016, David Budd will join Epistem on 1 March 2016.

David has over 20 years of international commercial and operational experience in the diagnostics and medical devices field, launching multiple diagnostics products into international markets. He joins from Leica Biosystems (a Danaher company), a fast growing organisation where he served as General Manager of Leica Biosystems Amsterdam. David previously served as Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, market research and product launches for diagnostic tests.

Prior to joining Leica Biosystems, David’s previous roles included Point-of-Care, molecular, and central laboratory marketing and commercialization responsibilities as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc.

- Ends –

For further details please contact:

Epistem Holdings Plc
Dr Ian Gilham: Chairman +44 (0)161 606 7258
John Rylands: Finance Director

Peel Hunt LLP
James Steel +44 (0)207 418 8900
Tom Burt
Oliver Jackson

Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Laura Thornton

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem’s Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: and

Record changed: 2016-02-28


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Epistem (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top